RxDoctor Payments Data

Michael Peters, MD

Family Medicine · Greer, SCNPI 1386902286

Payments from drug & device makers

$1,149in general payments, 2019–2025

Across 75 payments — averaging $15.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$162
  • Novo Nordisk$147
  • Lilly USA, LLC$134
  • AbbVie$105
  • Amgen$103
  • Takeda Pharmaceuticals U.S.A., Inc.$77
  • plus $420 from 11 others

What the payments were for

  • Food & beverage$1,149100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,149 in reported general payments places this provider in the 60th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$65,384
Medicare patients
170
Services billed
2,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$86,539
MounjaroTirzepatide32$33,841
EliquisApixaban29$32,714
RybelsusSemaglutide18$29,703
OzempicSemaglutide18$26,677
TrulicityDulaglutide21$23,941
GlyxambiEmpagliflozin/Linagliptin22$21,427
Victoza 3-PakLiraglutide14$18,993
Breo ElliptaFluticasone/Vilanterol12$13,486
MyrbetriqMirabegron13$10,390
Combivent RespimatIpratropium/Albuterol Sulfate14$9,615
Celecoxib148$9,022
Aimovig AutoinjectorErenumab-Aooe12$8,676
Tresiba Flextouch U-100Insulin Degludec11$5,144
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Glyxambi, Combivent Respimat$162$117,58096 claims
Lilly USA, LLCMounjaro, Trulicity$134$57,78253 claims
Novo NordiskRybelsus, Ozempic$147$56,38136 claims
PfizerEliquis$15$32,71429 claims
GSKBreo Ellipta, Arnuity Ellipta$64$17,56323 claims
MerckDulera$25$4,25212 claims
AbbVieSynthroid$105$1,56822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Greer

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →